Wanbury Secures New API Approvals to Expand Global Footprint

Wanbury Limited, a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs), has announced a strategic expansion of its product portfolio following successful quality inspections at its Tanuku facility in Andhra Pradesh. The company confirmed on June 10, 2026, that it has received the necessary regulatory clearances to begin shipments of three additional APIs to highly regulated international markets.

This development follows a period of robust operational growth for the company, which recently reported a 117% year-on-year surge in profit after tax for the fiscal year ended March 2026. The new API approvals are expected to further bolster Wanbury’s export capabilities, particularly as the firm seeks to deepen its presence in key regions, including Europe and Southeast Asia.

Facility Upgrades and Regulatory Milestones

The recent approvals at the Tanuku site come on the heels of a successful audit by the Ministry of Food and Drug Safety (MFDS) of South Korea at Wanbury's Patalganga plant in April 2026, which concluded with zero observations. These successive regulatory successes underscore Wanbury’s focus on maintaining high compliance standards across its manufacturing network.

According to company filings, the Tanuku facility has undergone significant capital expenditure to debottleneck production lines and enhance capacity. The site is now equipped to handle more complex chemical synthesis, supporting the company's recent move to launch specialized APIs, including anesthetic agents, for European markets.

Strategic Market Expansion

Wanbury is actively diversifying its geographic and product footprint. In recent regulatory filings, the company confirmed that it has submitted Drug Master Files (DMFs) for various molecules, including Diphenhydramine HCl, to regulatory bodies in Malaysia and Singapore. Simultaneously, the company is exploring new market opportunities for Paroxetine HCl in Korea and Latin America.

"According to officials, the latest approvals are a direct result of process optimizations and infrastructure investments made throughout the 2026 fiscal year, positioning the company to meet the rising demand for high-quality, cost-effective pharmaceutical ingredients," noted a company spokesperson in a recent briefing.

Financial Performance and Outlook

The company’s ability to secure these approvals has been a key driver of its positive financial trajectory. For FY26, Wanbury recorded a profit after tax of ₹66.1 crore, with EBITDA increasing 34.9% year-on-year to ₹107.7 crore. This growth has been supported by process innovations, better operating leverage, and the commercialization of new product lines from its manufacturing sites.

The firm's strategic focus remains on shifting toward higher-margin products and regulated markets, which now account for over 65% of its total revenue. By aligning its production capacity with international quality standards, Wanbury is aiming to solidify its status as a top-tier partner for global generic pharmaceutical manufacturers.

"According to officials, the Tanuku site is now fully prepared to meet the supply requirements for the three additional APIs, with commercial shipments already being integrated into the current logistical schedule."

Why It Matters

For global pharmaceutical companies and domestic stakeholders, Wanbury’s progress signals a reliable expansion in the supply of critical ingredients. As healthcare providers look to diversify their supply chains, Indian manufacturers that maintain rigorous quality certifications—such as USFDA, EU GMP, and KFDA—become increasingly essential. This move by Wanbury not only strengthens its export volume but also ensures it remains a competitive participant in the global market for specialized API synthesis.

Key Facts at a Glance

• Facility Milestone: Tanuku site cleared for the production and export of three additional APIs.

• Regulatory Status: Consecutive successes in international audits, including zero-observation ratings at the Patalganga plant.

• Market Growth: Revenue and profit growth driven by expansion into regulated markets like Europe, Korea, and Latin America.

• Revenue Milestone: FY26 profit after tax surged 117% to ₹66.1 crore.

FAQ

What do the new API approvals mean for Wanbury?

The approvals allow Wanbury to export three new pharmaceutical ingredients to international markets, expanding its product portfolio and revenue potential.

What is the significance of the zero-observation audit?

A zero-observation rating confirms that the manufacturing facility meets the highest international quality and safety standards, facilitating smoother drug approvals and exports.

Which markets is Wanbury targeting with these new APIs?

Wanbury is focused on regulated markets, specifically expanding in Europe, Southeast Asia (Malaysia, Singapore), South Korea, and Latin America.

How has the company's financial health evolved recently?

Wanbury reported strong growth in FY26, with profits more than doubling due to operational efficiency and the launch of new products.

Source: National Stock Exchange (NSE) Corporate Filings, Wanbury Limited Investor Relations, Indian Pharma Post, MoneyWorks4Me